Trials / Withdrawn
WithdrawnNCT01077167
Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Cytokinetics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to obtain a pharmacokinetic profile (i.e. amount of drug in the blood over time) of Omecamtiv mecarbil in patients with stable heart failure.
Detailed description
This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omecamtiv mecarbil | Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment. |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2010-02-26
- Last updated
- 2021-07-30
Source: ClinicalTrials.gov record NCT01077167. Inclusion in this directory is not an endorsement.